Psilera is delighted to mark a major preclinical achievement with a perfect record of accomplishment. Its first group of custom-made drug candidates have all been tested and found to have no hallucinogenic effects in animals – a remarkable feat! This selection incorporates six patent-pending compounds with distinct chemical structures, spanning four distinct families.
The latest drug candidates have been found to be non-hallucinogenic, yet still show promising results in treating a variety of mental health issues. In preclinical trials, these drugs have been observed to have a positive effect on mood disorders such as depression and anxiety, as well as improve cognitive functions like learning and memory.
Furthermore, they have been noted to have a positive effect on curbing alcohol addiction. This provides further evidence that therapeutic effects do not need to be linked to hallucinations, and similar compounds have even been referred to as “psychoplastogens”.
Psilera is on track to launch first-in-human trials in 2024, and the selection of a non-hallucinogenic drug as the lead compound holds many advantages. These benefits include patentability, take-home dosing, payer coverage, and increased accessibility for patients.
To ensure a successful launch, Psilera is utilizing animal data generated from the first six compounds to make an informed decision on the right lead compound.
Psilera Third Eye, a groundbreaking platform developed by a team of leading scientists, has predicted a new class of therapeutic compounds capable of providing relief without hallucinations.
Early experimental data suggests that these compounds have strong CNS receptor activity, and provisional patents have been filed to protect the innovative technology. With preclinical results used to hone the platform, these bespoke drug candidates could revolutionize the way we approach treatments.
Dr. Chris Witowski, Co-Founder and CEO of Psilera, is proud of the team’s hard work and dedication to create an extensive compound library that eliminates hallucinations while maintaining the desired effects.
This was achieved in a short time frame, with the lead compound now ready to be tested in the clinic – potentially becoming the first-in-class medicine of its kind. Psilera is excited to take the next step in this promising journey.
Psilera is revolutionizing the way we approach mental health, neurodegenerative disorders, and psychoactive natural products. With their cutting-edge drug discovery engine and technology-enabled platform, Psilera Third Eye, they are able to synthesize new compounds and design next-generation neurological drugs at the atomic level.
By leveraging the power of machine learning, they can identify lead non-hallucinogenic compounds while still providing therapeutic benefits. Psilera is enabling us to take control of our own health with their innovative new therapies, and bringing us into a new era of mindful medicine.